diagnosed or inadequately treated have micronutrient deficiencies -deficiencies in fat-soluble vitamins A, D, E, and K are commonly seen [2] . Zinc deficiency is prevalent in untreated adults with CD, and is in fact, the earliest and most pronounced nutritional deficiency in CD [3] . It is well known that in healthy people, zinc absorption is most efficient in the proximal small intestine, a region predominately affected by CD [3] . As zinc is a potent, competitive inhibitor of the calciuminduced activation of the transglutaminase type 2 enzyme (TG2), it moderates TG2 activation in the intestinal mucosa [4 ] . Thus, when zinc levels decrease in CD, and TG2 is activated, an immunologically mediated inflammation results in villous atrophy (Fig. 1a ). This damage causes a wide variety of consequences, including maldigestion and malabsorption of nutrients, vitamins, and minerals.
Low bone mineral density (BMD) is frequently found in subjects with CD [5] , as both the chronic inflammation and malabsorption can affect bone and mineral metabolism. Two main mechanisms are thought to be involved: an impaired intestinal absorption of nutrients that can lead to calcium deficiency, as well as general malnutrition and a reduced BMI; and the presence of inflammation and the chronic release of proinflammatory cytokines. Osteomalacia or osteoporosis appear to be secondary to the reduced calcium absorption, caused by atrophy of the intestinal villi, and/or to a vitamin D deficiency, leading to secondary hyperparathyroidism [6] . Recent studies [7 ,8] evaluated the association of bone fractures with CD. While Olmos et al. [7 ] conducted a meta-analysis to demonstrate the increased risk of fractures to be 43% greater in CD patients, Jafri et al. [8] determined the fracture incidence relative to matched controls in a The small intestine in active celiac disease (a) is manifested by villus atrophy, decreased enterocyte height, crypt hyperplasia, and IEL infiltration of the crypts. Gluten is presented by APCs in the lamina propria to CD4 T-cells after it has been deamidated by TG2. Local production of antibodies increases, with IgA antibodies secreted into the gut lumen as SIgA, and a spillover of IgA into the blood. Antibodies reactive with TG2 and deamidated gluten are typical of active CD. In Crohn's disease (b), there is mild flattening and broad thickening of the villi; there are noncaseating granulomas with (or without) giant cells that are distributed in patchy lesions, particularly affecting the terminal ileum. Compared with ulcerative colitis, Crohn's disease is transmural and granulomatous in character, occurring anywhere along the gastrointestinal tract. Crohn's disease is also characterized by hyperplasia of the submucosal nerves, sometimes called a 'neuromatous lesion'. In chronically HIV-infected patients (c), the small intestine is manifested by blunted villi, crypt hyperplasia, damage to the epithelial barrier with enterocyte apoptosis, and decreased luminal defensin (*). Also apparent is a massive CD4 T-cell depletion and high frequencies of infected CD4 T cells with release of virions. Increased membrane permeability and microbial translocation results from a breakdown of FAE tight junctions. In active ulcerative colitis (d), there is an absence of Goblet cells, crypt distortion, and abscess formation involving only the colonic mucosal layer. Compared with Crohn's disease, ulcerative colitis is superficial: the microscopic diagnosis of ulcerative colitis is based upon widespread mucosal distortion (shortened and branching crypts) and transmucosal inflammation with basal plasmacytosis. Activity can be recognized by the presence of neutrophils infiltrating the wall of some crypts. The mucosa may show bifid crypts characterized by the presence of double lumina. The diameter of the lumina and the intercryptal space are variable. APC, antigen-presenting cell; FAE, follicle-associated epithelium; IEL, intraepithelial lymphocyte; IgA, immunoglobulin A; sIgA, secretory IgA; TG2, transglutaminase type 2 enzyme population-based cohort with CD before and after diagnosis, and demonstrated that fracture risk is, in fact, 2-2.5-fold higher among patients with CD. Most significantly, the increase in fracture risk persisted after the diagnosis of CD. While it is evident that CD should be considered as one of the leading conditions predisposing to impaired bone health, additional research is necessary to identify predictors of the increased risk of fractures.
There is a general consensus on the need for a strict GFD [9] , but the need for micronutrient supplementation is less stressed and further investigation is needed. In contrast to wheat-containing products, very few gluten-free products are enriched or fortified, therefore, consuming a GFD increases the risk of prolonged micronutrient deficiencies. Gluten-free products are often low in B vitamins (thiamin, riboflavin, niacin, and folate), calcium, vitamin D, iron, zinc, magnesium, and fiber, especially soluble fiber [10 ] . In addition, some patients report food sensitivities and intolerances to dairy products, eggs, soy, and rice. While sensitivities to these food products may resolve once the small bowel heals, additional restrictions to the GFD increase the risk of overall nutritional deficiencies. Adherance to the GFD is important for villous repair: when CD patients commence with the GFD, TG2 antibodies, a key activator of intestinal inflammation, reportedly disappear. However, maintaining compliance on the GFD in adolescents is difficult, as Jadresin [11] recently reported that anemia was more common in subjects who were non-GFD compliant, thus increasing the risk for developing complications later in life.
Iron deficiency anemia (IDA) is frequently associated with CD, with the prevalence of IDA varying among reports, but typically ranging from 28% to 50% of patients diagnosed with CD [12] . Thus, it is recommended that iron supplementation be added to the GFD until iron stores have been restored. The process to normalize hemoglobin levels may take as long as 1 year, while it may take 2 years to replete iron stores [13] . In addition to IDA, patients with CD are predisposed to other hematologic abnormalities such as folate and vitamin B-12 deficiency. An investigation of anemia in more than 400 patients with CD reports that although iron deficiency was common (33% in men, 19% in women), folate deficiency (12%) and vitamin B-12 deficiency (5%) were also observed [14] . Anemia was present in approximately 20% of the cohort. Previously, Hallert et al. [15] assessed total plasma homocysteine (tHcy) levels in patients who had followed a GFD for 10 years, as a marker of B vitamin status. Compared with controls, persons following a GFD showed poorer vitamin status for folate and vitamins B-6 and B-12, even when taking nutrient supplements. In their follow-up study involving B vitamin supplementation for 6 months, Hallert et al. [10 ] now reports that patients with longstanding CD living on a GFD and taking supplemental B vitamins showed normalized tHcy and a significant improvement in general well-being, indicating that supplemental B vitamins should be considered in people with celiac disease who adhere to a GFD -specifically 0.8 mg folic acid/day (this is 2x the DRI, but does not exceed the upper limit (UL) of 1.0 mg/day), 0.5 mg vitamin B-12/day (as cyanocobalamin; while this exceeds the 2.4 mg/day DRI for adults, ULs have not been determined), and 3 mg vitamin B-6/day (the UL for adults (>19 years) is 100 mg B-6/day, as pyridoxine) should be considered [16] .
The use of micronutrient supplementation of GFDs for the treatment and prophylaxis of CD is supported by research findings. It has been suggested that the daily calcium intake in CD should be higher than the RDA (varies between 500-1000 mg for healthy adult) because of latent malabsorption in many patients [17] , and the increased fracture risk (see above). Further research regarding the type (and dose) of both calcium and vitamin D supplementation is needed to verify whether these adjuncts could improve BMD better than GFD alone. Zinc-fortified, gluten-free flour has the potential to treat, or even prevent CD, through the mechanism of zinc inhibiting TG2 in the intestinal tract. The administration of zinc is safe, well tolerated and inexpensive [18] , and could be a new component in the treatment of CD [19]however, further research is needed to confirm the role of zinc in the pathogenesis of CD. Recently, producers of GFD products initiated fortification strategies to increase the content of calcium, vitamin D, zinc, magnesium, niacin, riboflavin, thiamin, folate, vitamin B-6, and fiber for persons with CD (see Enjoy Life Foods http:// www.enjoylifefoods.com; and The Hain Celestial Group http://www.myglutenfreecafe.com).
In summary, vitamin and mineral supplementation can be a safe and useful adjunct therapy to the GFD by improving nutrient malabsorption and coexisting conditions related to nutritional deficiencies. The impact of mandated fortification and enrichment of GFD products would improve the quality of the diet long term, and warrants further evaluation.
Inflammatory bowel disease
IBD, including Crohn's disease and ulcerative colitis, is a major chronic disorder affecting the gastrointestinal tract in humans. Loftus et al. [20] reported that there were approximately 1.1 million people in the USA with IBD in the year 2000. The most common symptoms include anorexia or failure to thrive (in infants and children), abdominal pain, and diarrhea that may contain blood and mucous [21] . Although the etiopathogenesis of IBD has not been clearly elucidated, it is thought to involve a complex interplay among genetic, environmental, microbial, and immune factors. One potential pathogenic factor is impaired mucosal barrier function-intestinal hyperpermeability is common in IBD patients [22] ( Fig. 1b and d) .
Current guidelines recommend that active IBD should initially be treated with corticosteroids, followed by steroid-sparing drugs (e.g. azathioprine, mercaptopurine, methotrexate) once resistance or dependency develops. The development of osteoporosis following long-term corticosteroid therapy is a common nutritional complication of IBD -prevalence rates in patients with IBD range from 2% to 30% [23] , and the risk of fracture (symptomatic or asymptomatic) may be up to 40-60% higher than in the control population [23] . Together with corticosteroids, the inflammatory cytokines TNF-a and IL-6 have known adverse effects on bone metabolism: they impair bone formation through inhibition of osteoblast differentiation and function, and promote osteoblast apoptosis. These cytokines also accelerate bone resorption by osteoclasts [24] . Corticosteroids may also impair osteoclast adherence and function, potentially resulting in a state of low bone turnover.
Nutritional deficiencies occur early in the disease process and are often clinically evident at the time of diagnosis [25] . Valentini et al. [26 ] evaluated nutritional status, body composition, muscle strength, and quality of life in patients with IBD in clinical remission in a prospective, controlled, multicenter study. Most IBD patients (74%) were well nourished according to the subjective global assessment (SGA), BMI, and albumin levels; however, body composition assessments revealed a decrease in body cell mass in patients with Crohn's disease and ulcerative colitis compared with controls. In addition, the authors report that in both Crohn's disease and ulcerative colitis, micronutrient deficits (selenium, magnesium, vitamin B-12, and ferritin) are frequently seen in patients in remission. Similarly, Hengstermann et al. [27] also evaluated nutritional and antioxidant vitamin status in patients with IBD in remission and found decreased levels of vitamin C, lycopene, lutein/zeaxanthin, b-cryproxanthin, a, b-carotenes and total carotenoids despite good nutritional status (based on SGA, BMI, albumin levels), and low levels of inflammation. Thus, micronutrient supplementation is an issue even in patients with IBD in clinical remission.
Anemia is such a common complication of IBD that it is almost invariably not investigated, and rarely treated [28] . New evidence indicates that anemia in IBD patients should be investigated with care because many factors can be responsible [29] . For treatment of active inflammation, oral iron supplementation might be of limited efficacy, hence iv iron should be administered as it is considered both safe and effective in the treatment of iron deficiency anemia in IBD patients [30 ] . The absorption deficiency of vitamin B-12 in IBD contributes to the anemia and to hypercoagulability. The resection or involvement of the terminal ileum in Crohn's requires vitamin B-12 supplementation via the parental route. Thus, anemia diagnosis and treatment should not be neglected in IBD patients.
Micronutrient recommendations for IBD patients undergoing corticosteroid therapy should be based on the strengths of the evidence, and the dietary reference intakes, to help prevent deficiencies. Moorthy et al. [31] published the following recommendations aimed at correcting deficiencies and preventing bone loss in Crohn's disease patients:
( Recently, the role of zinc in membrane barrier function has been demonstrated both in vitro [32 ] and in vivo [33] . Depletion of zinc reportedly caused phosphorylationmediated disruption of junctional complexes and cytoskeleton disorganization in Caco2 cells, thus promoting the migration of neutrophils [32 ] ; while zinc supplementation reportedly reduced intestinal permeability in weanling pigs [33] . These results may explain the findings that patients with IBD and low mucosal zinc concentration typically present an accumulation of neutrophils in epithelial crypts and intestinal lumen resulting in the formation of crypt abscesses [34] . This provides new information on the critical role of dietary zinc in the maintenance of membrane barrier function and in controlling inflammatory reactions. Mahmood et al. [35] reported using a zinc supplement to stabilize integrity and stimulate repair processes in well validated in-vitro and in-vivo models, and in a clinical trial. Healthy volunteers undertook a randomized crossover trial comparing changes in gut permeability (lactulose:rhamnose ratios) before and after 5 days of indomethacin treatment with zinc carnosine (ZnC; 37.5 mg of ZnC twice daily, providing 8 mg elemental Zn twice daily) or placebo coadministration. They conclude that ZnC, at concentrations likely to be found in the gut lumen, stabilizes gut mucosa.
In summary, nutritional derangements are frequent in IBD. In the past year significant work has been published examining micronutrient deficiencies that either arise from the disease, or are initiated as a result of therapy. The potential role of select micronutrients, including zinc, to address anemia in IBD is particularly addressed.
HIV/AIDS-related diarrhea
HIV/AIDS-related diarrhea is an important cause of morbidity and mortality in HIV infection, especially in sub-Saharan Africa where 70% of deaths from HIV occur. HIV-enteropathy involves diarrhea, increased GI inflammation with massive CD4 T-cell depletion and viral infections throughout [36 ] , and increased intestinal permeability (up to 5x higher than in healthy controls). Histologically, the enterocyte apoptosis involves inflammatory infiltrates of lymphocytes and damage to the GI epithelial layer, including villous atrophy, crypt hyperplasia, disruption of tight epithelial junctions and villous blunting [37] . HIV infection could quite reasonably be considered a disease of the GI tract (Fig. 1c ).
Diarrhea often compromises the quality of life both in those receiving highly active antiretroviral therapy (HAART) and the HAART naive. Most observational studies investigating the micronutrient status of HIVinfected populations not receiving HAART have reported low serum or plasma levels of micronutrients such as vitamins A, E, thiamine, niacin, B-6, B-12, C, D and carotenoids, as well as trace elements such as zinc and selenium. These micronutrient deficiencies are associated with either low CD4 cell counts, advanced HIV-related diseases, faster disease progression, or HIV-related mortality [38] . In HIV infected individuals, vitamin A deficiency (VAD; serum retinol < 0.70 mmol/L) is associated with the development of HIV-related disease sequelae and increased progression to AIDS and death. VAD may also lead to alterations in immunity, including pathological changes in the mucosal surfaces, impaired antibody responses to challenge protein antigens, decreased CD4 cell populations, and altered T and B-cell functions. During HIV infection, VAD has been associated with increased immune abnormalities, high mother-to-child transmission of HIV, higher infant mortality, and increased breast milk viral burden. Recently, Kassu et al. [39] reported that VAD was observed in 53% of diarrheic patients with HIV co-infection in Ethiopia. In addition, 29% of asymptomatic HIV-infected blood donors were deficient in vitamin A. The levels of serum vitamin A were not associated with the presence of intestinal parasites or Shigella species. While the study was conducted in northern Ethiopia, the finding that VAD is a severe public health problem among diarrheic patients with HIV may have implications for intervention programs elsewhere involving health and nutrition education -vitamin A supplementation might help to reduce morbidity in such patients.
As current HAART regimens allow for only partial repair of the gastrointestinal damage that results from HIV infection [36 ] , empirical antidiarrheal treatment may be required in about 50% of cases, which are either nonpathogenic or idiopathic [40] . As vitamin A supplementation reduces the risk of diarrhea-related morbidity and mortality and 'all-risk' mortality in HIV-infected and uninfected children under 5 years of age [41] , children should be supplemented with 50,000 IU of vitamin A at 1 and 3 months, 100,000 IU at 6 and 9 months and 200,000 IU at 12 and 15 months. Further supplementation with 200,000 IU 6-monthly thereafter until the age of 5 years is also recommended. There is also evidence that zinc supplementation enhances host defense [42,43 ,44-46] , including reduced diarrhea in HIV-infected children [47] . Recently, Chhagan [48] reported on the efficacy of using a daily micronutrient supplement that included both zinc (10 mg as zinc gluconate) and vitamin A (1250 IU) to reduce diarrhea incidence in HIV-infected children. In addition to zinc and vitamin A, the supplement also contained 0.5 mg each of vitamins B-1, B-2 and B-6; 0.9 mg vitamin B-12; 35 mg vitamin C; 5 mg vitamin D; 6 mg vitamin E; 10 mg vitamin K; 0.6 mg copper; 150 mg folate; 50 mg iodine; 10 mg iron as ferrous fumarate and 6 mg niacin. Compared with vitamin A alone, supplementation with zinc with (or, without) multiple micronutrients, reduced diarrhea morbidity in rural South African children with HIV.
Patients with HIV/AIDS-related diarrhea might also experience zinc deficiencies as zinc losses in diarrhea occur via apoptosis of epithelial cells lining the intestinal mucosa or via salivary glands, pancreatic, biliary and intestinal cell secretion. Fecal loss may range from less than 1 mg/day with a zinc-poor diet, up to 5 mg/day with a zinc-rich diet [49] . Until recently, the mechanisms of this effect were largely undefined -Canani et al. [50 ] has now shown that Tat (transactivating peptide produced by HIV-1) has a role in the pathogenesis of diarrhea in AIDS patients. They showed in vitro that zinc directly limits a specific mechanism of AIDS-related diarrhea by preventing Tat-induced fluid secretion. As zinc has a fundamental impact in sustaining cellular immunity, their data support a ''Zn-approach'' in adjunct to specific antiretroviral therapy in AIDS-infected patients. Hence, studies evaluating the potential benefit(s) from zinc supplementation for either prevention, or treatment of diarrhea in AIDS patients are warranted.
In contrast with the evidence that micronutrients confer benefit in HIV-infected children, fewer data are available relating to adults with HIV infection. Allen et al.
[51 ] performed random-effects meta-analyses of randomized controlled trials (RCTs) for the effects of multiple micronutrients in adults. They conclude that, in adults, multiple micronutrient supplementation improves CD4 cell counts and HIV-related morbidity and mortality. These benefits include a reduction in some gastrointestinal manifestations [52, 53] and a reduction in mortality [52, 54] . New information is now available on the impact of physiologic doses of micronutrients in populations that would be expected to have micronutrient deficiencies.
Kelly et al. [55] reported on the effects of HIV on intestinal barrier function in a longitudinal cohort study carried out in Zambia over 3 years. The authors demonstrated that HIV impacted intestinal infection at all stages, with an increased disease-to-infection ratio.
The aggregation of disease in HIV infection, irrespective of CD4 cell count, suggests that this phenomenon is not a function of cell-mediated immunity. Although HAART reportedly reduces gastrointestinal immune activation, the ability of the remaining but damaged lymphoid niche to support significant CD4 T-cell reconstitution may be permanently damaged [36 ] . In a concurrent study, Kelly et al. [52] tested whether the defense against intestinal infection was dependent on micronutrient status in a RCT of multiple micronutrient supplementation in a population in which there was borderline micronutrient deficiency. Five hundred participants were given a daily tablet containing 15 micronutrients at just above the recommended nutrient intake, or a placebo. The tablet included 15 mg zinc and 4.8 mg vitamin A (as b-carotene).
The study objectives included incidence and severity of diarrhea, nutritional status, CD4 cell count, and mortality. The incidence of diarrhea (1.4 episodes/year/ person) did not differ with treatment allocation. Importantly, both severe episodes of diarrhea and mortality were reduced in the group receiving multiple micronutrient supplementation; however, this was not due to changes in CD4 cell count or nutritional status. Thus, future research needs to confirm the efficacy of zinc and/ or vitamin A supplementation for reducing diarrhearelated morbidity in HIV-infected adults.
A recent Cochrane review [56] of 15 micronutrient trials in HIV-infected subjects noted no effect of vitamin A or b-carotene on mortality, morbidity, viral load or CD4 cell levels. While the authors agree that it is reasonable to support the WHO's recommendations to promote the adequate dietary intake of micronutrients at RDA levels, and to provide vitamin A supplementation to children, they did note that 'there is no conclusive evidence at present to show that micronutrient supplementation effectively reduces mortality and morbidity among HIV-infected adults'. Clearly, huge gaps in knowledge remain. Many HIV-infected patients are poor and unemployed and malnutrition is common, particularly among children. Thus, any intervention strategy should provide for both macro-and micro-nutrient supplementation of those in need. The HIV-infected must be identified and offered assistance before malnutrition becomes overt. Adequate nutrition must be provided together with HAART. Controlling the virus without providing food and micronutrients will not restore body weight or correct metabolic and cellular function in the malnourished.
It is important to note that, to date, most multiple-micronutrient intervention studies have major limitations, including an inadequate assessment of HIV-related outcomes, a short duration of follow-up, a small sample size, and a lack of adjustment for inflammatory markers [38] . Therefore, few data are available to recommend or refute the benefit of providing micronutrient supplements to HIV-positive persons in the HAART era. Because micronutrient supplementation may cause harm, RCT's are also needed. Future research should determine whether HAART initiation restores micronutrient concentrations, independent of inflammatory markers, and whether micronutrient supplements affect HIV-related outcomes in HIV positive persons receiving HAART.
Conclusion
The evidence supporting micronutrient combinations to combat gastrointestinal inflammation is strong, and the transition from conducting research to formulating policy is being facilitated by the low cost of most supplements. Additional preventive approaches are needed to combat gastrointestinal inflammation, including food fortification and other food-based approaches that may increase the intake of multiple micronutrients, and improve nutritional status. To reduce HIV/AIDS-related diarrhea, there is global support for the adaptation of zinc and vitamin A supplementation at the country level [18] , and, although the cost of supplemental zinc is inexpensive (approximately $0.20 per full course of treatment), financing initial supplies at the country level has thus far been an additional challenge [57] .
The major challenges of the future are performing welldesigned clinical studies in patients to confirm anticipated effects, to define the optimal doses, to compare single vs. multiple micronutrient supplement trials, and to assess possible side-effects.
